Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pfizer Acquires Biohaven for $11.6B

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon May 18, 2022 7:51pm

159 Views

Post# 34694124

RE:RE:Pfizer Acquires Biohaven for $11.6B

To summerize, Dr. Wallace would say, "Good science takes time"

when it comes to the actual research and trials, speed cannot be the driving priority....and it has to be safe, for as many people as possible. No matter what it’s for, good science takes time

https://herald-review.com/opinion/columnists/john-l-wallace-good-science-takes-time/article_5490aa73-8c29-564e-88d2-c4f5646af7fa.html

MrMugsy wrote:

Forestview wrote: Could pharmaceutical acquisitions be starting up again...this is Pfizer's first acquisition since 2017.

https://www.siliconrepublic.com/business/pfizer-biohaven-acquisition-migraine-nurtec-odt-medication#:~:text=Acquiring%20Biohaven%20will%20allow%20Pfizer,that%20treat%20and%20prevent%20migraines

There are many reasons why Big Pharma needs to really work on their future drug portfolios - from governments looking to get pricing down - to some Big Pharmas who made bad calls on acquisitions (Bayer and Round-up) - to CEOs getting ousted (Biogen - AD) - to big drugs coming off patent by 2026-2030. There are many reasons why Big Pharma needs to make wise decisions.

We're just not in the running in 2022 (IMO) - but that's OK ... stars are aligning ... especially when you look at the cost of opioids going up (disposal education/stamped envelopes for disposal), Doctors not wanting to deal with opioids and better education out there about the damage from NSAIDs (specifically Aspirin right now).

It's going to get really interesting - I think.